{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:58:52Z","timestamp":1780498732988,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Key Project of Health Commission of Zhejiang Province","award":["WKJ-ZJ-2023"],"award-info":[{"award-number":["WKJ-ZJ-2023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To explore the global research trends, hotspots and frontiers of optic neuritis (ON) over the past decade through qualitative and quantitative analysis of bibliometrics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Publications on ON from 2013 to 2022 were retrieved from Web of Science Core Collection (WoSCC). VOSviewer and CiteSpace were mainly used to facilitate bibliometric analysis and visualization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 3027 papers were retrieved from peer-reviewed publications and the annual research output increased over time. Neurosciences neurology was the most published area. The USA was the most productive and influential country, and in the focus of international cooperation. University College London was the most productive organization and Charite Medical\u00a0University\u00a0of\u00a0Berlin had the largest number of cooperating partners. Paul F contributed the largest number of publications and Wingerchuk DM ranked\u00a0first\u00a0among the\u00a0co-cited\u00a0authors. <jats:italic>Multiple Sclerosis and Related Disorders<\/jats:italic> was the most prolific journal publishing ON research. The most co-cited references mainly focused on the diagnostic criteria for neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS). The keywords formed the following four clusters: the pathophysiology of MS-ON; the autoantibody markers and diagnostic criteria of NMOSD-ON and myelin oligodendrocyte glycoprotein associated disorder-ON (MOGAD-ON); the epidemiology and clinical characteristics of ON; and the treatment of ON.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This bibliometrics analysis showed a systematic view of the evolutionary process, research hotspots, and future directions of ON research. It can provide insights for ON research and valuable information for neuro-ophthalmologic specialists to evaluate research policies and promote international cooperation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10792-024-02948-7","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T03:04:08Z","timestamp":1707707048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Visualization and analysis of mapping knowledge domains for optic neuritis: a bibliometric research from 2013 to 2022"],"prefix":"10.1007","volume":"44","author":[{"given":"Bo","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangkun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"2948_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","volume":"13","author":"AT Toosy","year":"2014","unstructured":"Toosy AT, Mason DF, Miller DH (2014) Optic neuritis. Lancet Neurol 13:83\u201399. https:\/\/doi.org\/10.1016\/S1474-4422(13)70259-X","journal-title":"Lancet Neurol"},{"key":"2948_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01658107.2021.1964541","volume":"46","author":"SJ Hickman","year":"2022","unstructured":"Hickman SJ, Petzold A (2022) Update on optic neuritis: an international view. Neuroophthalmology 46:1\u201318. https:\/\/doi.org\/10.1080\/01658107.2021.1964541","journal-title":"Neuroophthalmology"},{"key":"2948_CR3","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","volume":"21","author":"A Petzold","year":"2022","unstructured":"Petzold A, Fraser CL, Abegg M et al (2022) Diagnosis and classification of optic neuritis. Lancet Neurol 21:1120\u20131134. https:\/\/doi.org\/10.1016\/S1474-4422(22)00200-9","journal-title":"Lancet Neurol"},{"key":"2948_CR4","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J et al (2018) Multiple sclerosis. Lancet 391:1622\u20131636. https:\/\/doi.org\/10.1016\/S0140-6736(18)30481-1","journal-title":"Lancet"},{"key":"2948_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41433-020-01334-8","volume":"35","author":"SM Gospe 3rd","year":"2021","unstructured":"Gospe SM 3rd, Chen JJ, Bhatti MT (2021) Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye (Lond) 35:753\u2013768. https:\/\/doi.org\/10.1038\/s41433-020-01334-8","journal-title":"Eye (Lond)"},{"key":"2948_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41433-017-0010-2","volume":"32","author":"J Britze","year":"2018","unstructured":"Britze J, Frederiksen JL (2018) Optical coherence tomography in multiple sclerosis. Eye (Lond) 32:884\u2013888. https:\/\/doi.org\/10.1038\/s41433-017-0010-2","journal-title":"Eye (Lond)"},{"key":"2948_CR7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/ICO.0000000000001984","volume":"38","author":"F Zhao","year":"2019","unstructured":"Zhao F, Du F, Zhang J et al (2019) Trends in research related to keratoconus from 2009 to 2018: a bibliometric and knowledge mapping analysis. Cornea 38:847\u2013854. https:\/\/doi.org\/10.1097\/ICO.0000000000001984","journal-title":"Cornea"},{"key":"2948_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.991099","volume":"13","author":"Y Huang","year":"2022","unstructured":"Huang Y, Gong Y, Liu Y et al (2022) Global trends and hot topics in electrical stimulation of skeletal muscle research over the past decade: a bibliometric analysis. Front Neurol 13:991099. https:\/\/doi.org\/10.3389\/fneur.2022.991099","journal-title":"Front Neurol"},{"key":"2948_CR9","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1007\/s10792-022-02380-9","volume":"42","author":"J Xu","year":"2022","unstructured":"Xu J, Zhao F, Fang J et al (2022) Mapping research trends of chronic ocular graft-versus-host disease from 2009 to 2020: a bibliometric analysis. Int Ophthalmol 42:3963\u20133976. https:\/\/doi.org\/10.1007\/s10792-022-02380-9","journal-title":"Int Ophthalmol"},{"key":"2948_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jconrel.2022.03.031","volume":"345","author":"C Peng","year":"2022","unstructured":"Peng C, Kuang L, Zhao J et al (2022) Bibliometric and visualized analysis of ocular drug delivery from 2001 to 2020. J Control Release Off J Control Release Soc 345:625\u2013645. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.031","journal-title":"J Control Release Off J Control Release Soc"},{"key":"2948_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84:523\u2013538. https:\/\/doi.org\/10.1007\/s11192-009-0146-3","journal-title":"Scientometrics"},{"key":"2948_CR12","first-page":"334","volume":"65","author":"C Chen","year":"2014","unstructured":"Chen C, Leydesdorff L (2014) Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis. J Am Soc Inf Sci 65:334\u2013351","journal-title":"J Am Soc Inf Sci"},{"key":"2948_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fphar.2020.00294","volume":"11","author":"C Lu","year":"2020","unstructured":"Lu C, Liu M, Shang W et al (2020) Knowledge mapping of Angelica sinensis (Oliv.) Diels (Danggui) research: a scientometric study. Front Pharmacol 11:294. https:\/\/doi.org\/10.3389\/fphar.2020.00294","journal-title":"Front Pharmacol"},{"key":"2948_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474\u2013481. https:\/\/doi.org\/10.1212\/WNL.0000000000000101","journal-title":"Neurology"},{"key":"2948_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"2948_CR16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485\u20131489. https:\/\/doi.org\/10.1212\/01.wnl.0000216139.44259.74","journal-title":"Neurology"},{"key":"2948_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"2948_CR18","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K et al (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381:614\u2013625. https:\/\/doi.org\/10.1056\/NEJMoa1900866","journal-title":"N Engl J Med"},{"key":"2948_CR19","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","volume":"6","author":"H Stiebel-Kalish","year":"2019","unstructured":"Stiebel-Kalish H, Hellmann MA, Mimouni M et al (2019) Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol R Neuroimmunol Neuroinflam 6:e572. https:\/\/doi.org\/10.1212\/NXI.0000000000000572","journal-title":"Neurol R Neuroimmunol Neuroinflam"},{"key":"2948_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Ann Neurol"},{"key":"2948_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79:1273\u20131277. https:\/\/doi.org\/10.1212\/WNL.0b013e31826aac4e","journal-title":"Neurology"},{"key":"2948_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley J, Waters P, Woodhall M et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71:276\u2013283. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5857","journal-title":"JAMA Neurol"},{"key":"2948_CR23","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106\u20132112. https:\/\/doi.org\/10.1016\/S0140-6736(04)17551-X","journal-title":"Lancet"},{"key":"2948_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1474-4422(17)30278-8","volume":"16","author":"A Petzold","year":"2017","unstructured":"Petzold A, Balcer LJ, Calabresi PA et al (2017) Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 16:797\u2013812. https:\/\/doi.org\/10.1016\/S1474-4422(17)30278-8","journal-title":"Lancet Neurol"},{"key":"2948_CR25","doi-asserted-by":"publisher","first-page":"e0183957","DOI":"10.1371\/journal.pone.0183957","volume":"12","author":"M Puthenparampil","year":"2017","unstructured":"Puthenparampil M, Federle L, Poggiali D et al (2017) Trans-synaptic degeneration in the optic pathway: a study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis. PLoS ONE 12:e0183957. https:\/\/doi.org\/10.1371\/journal.pone.0183957","journal-title":"PLoS ONE"},{"key":"2948_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/ana.25462","volume":"85","author":"RC Nolan-Kenney","year":"2019","unstructured":"Nolan-Kenney RC, Liu M, Akhand O et al (2019) Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: an international study. Ann Neurol 85:618\u2013629. https:\/\/doi.org\/10.1002\/ana.25462","journal-title":"Ann Neurol"},{"key":"2948_CR27","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458514567216","volume":"21","author":"JL Bennett","year":"2015","unstructured":"Bennett JL, de Seze J, Lana-Peixoto M et al (2015) Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler 21:678\u2013688. https:\/\/doi.org\/10.1177\/1352458514567216","journal-title":"Mult Scler"},{"key":"2948_CR28","first-page":"382","volume":"54","author":"G Yousefipour","year":"2016","unstructured":"Yousefipour G, Hashemzahi Z, Yasemi M et al (2016) Findings of optical coherence tomography of retinal nerve fiber layer in two common types of multiple sclerosis. Acta Med Iran 54:382\u2013390","journal-title":"Acta Med Iran"},{"key":"2948_CR29","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1111\/ene.14421","volume":"27","author":"A Vidal-Jordana","year":"2020","unstructured":"Vidal-Jordana A, Pareto D, Cabello S et al (2020) Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease-related disability. Eur J Neurol 27:2225\u20132232. https:\/\/doi.org\/10.1111\/ene.14421","journal-title":"Eur J Neurol"},{"key":"2948_CR30","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3109\/02713683.2015.1119283","volume":"41","author":"E Esen","year":"2016","unstructured":"Esen E, Sizmaz S, Balal M et al (2016) Evaluation of the innermost retinal layers and visual evoked potentials in patients with multiple sclerosis. Curr Eye Res 41:1353\u20131358. https:\/\/doi.org\/10.3109\/02713683.2015.1119283","journal-title":"Curr Eye Res"},{"key":"2948_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.29399\/npa.27355","volume":"58","author":"C Uzunkopru","year":"2021","unstructured":"Uzunkopru C, Yuceyar N, Yilmaz SG et al (2021) Retinal nerve fiber layer thickness correlates with serum and cerebrospinal fluid neurofilament levels and is associated with current disability in multiple sclerosis. Noro psikiyatri arsivi 58:34\u201340. https:\/\/doi.org\/10.29399\/npa.27355","journal-title":"Noro psikiyatri arsivi"},{"key":"2948_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.618879","volume":"11","author":"OC Murphy","year":"2020","unstructured":"Murphy OC, Kalaitzidis G, Vasileiou E et al (2020) Optical coherence tomography and optical coherence tomography angiography findings after optic neuritis in multiple sclerosis. Front Neurol 11:618879. https:\/\/doi.org\/10.3389\/fneur.2020.618879","journal-title":"Front Neurol"},{"key":"2948_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/WNO.0000000000000802","volume":"40","author":"JK Chan","year":"2020","unstructured":"Chan JK, Martinez H, de Lapiscina E, Taylor C et al (2020) Long-term stability of neuroaxonal structure in alemtuzumab-treated relapsing-remitting multiple sclerosis patients. J Neuroophthalmol 40:37\u201343. https:\/\/doi.org\/10.1097\/WNO.0000000000000802","journal-title":"J Neuroophthalmol"},{"key":"2948_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/1352458517750009","volume":"25","author":"N Feucht","year":"2019","unstructured":"Feucht N, Maier M, Lepennetier G et al (2019) Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis. Mult Scler 25:224\u2013234. https:\/\/doi.org\/10.1177\/1352458517750009","journal-title":"Mult Scler"},{"key":"2948_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473\u2013477. https:\/\/doi.org\/10.1084\/jem.20050304","journal-title":"J Exp Med"},{"key":"2948_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14. https:\/\/doi.org\/10.1186\/1742-2094-9-14","journal-title":"J Neuroinflammation"},{"key":"2948_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflam 15:134. https:\/\/doi.org\/10.1186\/s12974-018-1144-2","journal-title":"J Neuroinflam"},{"key":"2948_CR38","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","volume":"139","author":"R Hoftberger","year":"2020","unstructured":"Hoftberger R, Guo Y, Flanagan EP (2020) The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 139:875\u2013892. https:\/\/doi.org\/10.1007\/s00401-020-02132-y","journal-title":"Acta Neuropathol"},{"key":"2948_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","volume":"11","author":"JY Hor","year":"2020","unstructured":"Hor JY, Asgari N, Nakashima I et al (2020) Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 11:501. https:\/\/doi.org\/10.3389\/fneur.2020.00501","journal-title":"Front Neurol"},{"key":"2948_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/archneur.65.6.727","volume":"65","author":"Optic Neuritis Study G","year":"2008","unstructured":"Optic Neuritis Study G (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727\u2013732. https:\/\/doi.org\/10.1001\/archneur.65.6.727","journal-title":"Arch Neurol"},{"key":"2948_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J et al (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.020","journal-title":"Am J Ophthalmol"},{"key":"2948_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","volume":"19","author":"S Huda","year":"2019","unstructured":"Huda S, Whittam D, Bhojak M et al (2019) Neuromyelitis optica spectrum disorders. Clin Med 19:169\u2013176. https:\/\/doi.org\/10.7861\/clinmedicine.19-2-169","journal-title":"Clin Med"},{"key":"2948_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.866824","volume":"13","author":"A Dinoto","year":"2022","unstructured":"Dinoto A, Sechi E, Flanagan EP et al (2022) Serum and cerebrospinal fluid biomarkers in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disease. Front Neurol 13:866824. https:\/\/doi.org\/10.3389\/fneur.2022.866824","journal-title":"Front Neurol"},{"key":"2948_CR44","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/jnc.15478","volume":"159","author":"C Liu","year":"2021","unstructured":"Liu C, Lu Y, Wang J et al (2021) Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: a cohort study. J Neurochem 159:913\u2013922. https:\/\/doi.org\/10.1111\/jnc.15478","journal-title":"J Neurochem"},{"key":"2948_CR45","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4103\/ijo.IJO_2235_21","volume":"70","author":"A Jossy","year":"2022","unstructured":"Jossy A, Jacob N, Sarkar S et al (2022) COVID-19-associated optic neuritis: a case series and review of literature. Indian J Ophthalmol 70:310\u2013316. https:\/\/doi.org\/10.4103\/ijo.IJO_2235_21","journal-title":"Indian J Ophthalmol"},{"key":"2948_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/11206721221118736","author":"V Pirani","year":"2022","unstructured":"Pirani V, Pelliccioni P, Carpene MJ et al (2022) Optic neuritis following COVID-19 vaccination: Do autoimmune diseases play a role? Eur J Ophthalmol. https:\/\/doi.org\/10.1177\/11206721221118736","journal-title":"Eur J Ophthalmol"},{"key":"2948_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2022.2089901","author":"B Shirah","year":"2022","unstructured":"Shirah B, Mulla I, Aladdin Y (2022) Optic neuritis following the BNT162b2 mRNA COVID-19 vaccine in a patient with systemic lupus erythematosus uncovering the diagnosis of neuromyelitis optica spectrum disorders. Ocular Immunol Inflam. https:\/\/doi.org\/10.1080\/09273948.2022.2089901","journal-title":"Ocular Immunol Inflam"},{"key":"2948_CR48","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","volume":"75","author":"SA Morrow","year":"2018","unstructured":"Morrow SA, Fraser JA, Day C et al (2018) Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol 75:690\u2013696. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0024","journal-title":"JAMA Neurol"},{"key":"2948_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/jnnp-2019-321653","volume":"91","author":"A Petzold","year":"2020","unstructured":"Petzold A, Braithwaite T, van Oosten BW (2020) Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. J Neurol Neurosurg Psychiatry 91:9\u201314. https:\/\/doi.org\/10.1136\/jnnp-2019-321653","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2948_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458515581438","volume":"22","author":"H Abboud","year":"2016","unstructured":"Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M (2016) Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 22:185\u2013192. https:\/\/doi.org\/10.1177\/1352458515581438","journal-title":"Mult Scler"},{"key":"2948_CR51","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","volume":"89","author":"M Bonnan","year":"2018","unstructured":"Bonnan M, Valentino R, Debeugny S et al (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89:346\u2013351. https:\/\/doi.org\/10.1136\/jnnp-2017-316286","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2948_CR52","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jca.21686","volume":"34","author":"M Lipphardt","year":"2019","unstructured":"Lipphardt M, Muhlhausen J, Kitze B et al (2019) Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica. J Clin Apheresis 34:381\u2013391. https:\/\/doi.org\/10.1002\/jca.21686","journal-title":"J Clin Apheresis"},{"key":"2948_CR53","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/1756285616646332","volume":"9","author":"S Faissner","year":"2016","unstructured":"Faissner S, Nikolayczik J, Chan A et al (2016) Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord 9:281\u2013286. https:\/\/doi.org\/10.1177\/1756285616646332","journal-title":"Ther Adv Neurol Disord"},{"key":"2948_CR54","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1468-1331.2008.02258.x","volume":"15","author":"A Tselis","year":"2008","unstructured":"Tselis A, Perumal J, Caon C et al (2008) Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 15:1163\u20131167. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02258.x","journal-title":"Eur J Neurol"},{"key":"2948_CR55","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s10384-020-00790-9","volume":"65","author":"O Mimura","year":"2021","unstructured":"Mimura O, Ishikawa H, Kezuka T et al (2021) Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study. Jpn J Ophthalmol 65:122\u2013132. https:\/\/doi.org\/10.1007\/s10384-020-00790-9","journal-title":"Jpn J Ophthalmol"},{"key":"2948_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-022-00932-1","author":"H Song","year":"2022","unstructured":"Song H, Zhou H, Wei S (2022) Update on glial antibody-mediated optic neuritis. Jpn J Ophthalmol. https:\/\/doi.org\/10.1007\/s10384-022-00932-1","journal-title":"Jpn J Ophthalmol"},{"key":"2948_CR57","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1212\/WNL.0000000000007312","volume":"92","author":"H Hayward-Koennecke","year":"2019","unstructured":"Hayward-Koennecke H, Reindl M, Martin R et al (2019) Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis. Neurology 92:765\u2013767. https:\/\/doi.org\/10.1212\/WNL.0000000000007312","journal-title":"Neurology"},{"key":"2948_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103310","volume":"56","author":"S Thakolwiboon","year":"2021","unstructured":"Thakolwiboon S, Zhao-Fleming H, Karukote A et al (2021) Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder. Multiple Sclerosis Relat Disord 56:103310. https:\/\/doi.org\/10.1016\/j.msard.2021.103310","journal-title":"Multiple Sclerosis Relat Disord"},{"key":"2948_CR59","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s13311-022-01206-x","volume":"19","author":"V Redenbaugh","year":"2022","unstructured":"Redenbaugh V, Flanagan EP (2022) Monoclonal antibody therapies beyond complement for NMOSD and MOGAD. Neurother J Am Soc Exp NeuroTher 19:808\u2013822. https:\/\/doi.org\/10.1007\/s13311-022-01206-x","journal-title":"Neurother J Am Soc Exp NeuroTher"},{"key":"2948_CR60","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","volume":"15","author":"R Raftopoulos","year":"2016","unstructured":"Raftopoulos R, Hickman SJ, Toosy A et al (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15:259\u2013269. https:\/\/doi.org\/10.1016\/S1474-4422(16)00004-1","journal-title":"Lancet Neurol"},{"key":"2948_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/WNO.0000000000000697","volume":"39","author":"J Petrillo","year":"2019","unstructured":"Petrillo J, Balcer L, Galetta S et al (2019) Initial impairment and recovery of vision-related functioning in participants with acute optic neuritis from the RENEW trial of opicinumab. J Neuroophthalmol 39:153\u2013160. https:\/\/doi.org\/10.1097\/WNO.0000000000000697","journal-title":"J Neuroophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-02948-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-02948-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-02948-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:44:20Z","timestamp":1741880660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-02948-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2948"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-02948-7","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"23 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"57"}}